TY  - JOUR
AU  - Marquez-Rodas, Ivan
AU  - Alvarez, Ana
AU  - Arance, Ana
AU  - Valduvieco, Izaskun
AU  - Berciano-Guerrero, Miguel-angel
AU  - Delgado, Raquel
AU  - Soria, Ainara
AU  - Lopez-Campos, Fernando
AU  - Sanchez, Pedro
AU  - Romero, Jose Luis
AU  - Martin-Liberal, Juan
AU  - Lucas, Anna
AU  - Diaz-Beveridge, Roberto
AU  - Conde-Moreno, Antonio-Jose
AU  - Alamo-de-la-Gala, Maria del Carmen
AU  - Garcia-Castano, Almudena
AU  - Prada, Pedro Jose
AU  - Gonzalez-Cao, Maria
AU  - Puertas, Enrique
AU  - Vidal, Joana
AU  - Foro, Palmira
AU  - Aguado-de-la-Rosa, Carlos
AU  - Corona, Juan Antonio
AU  - Cerezuela-Fuentes, Pablo
AU  - Lopez, Paco
AU  - Luna, Pablo
AU  - Aymar, Neus
AU  - Puertolas, Teresa
AU  - Sanagustin, Pilar
AU  - Berrocal, Alfonso
PY  - 2024
DO  - 10.1093/neuonc/noae116
SN  - 1522-8517
UR  - https://hdl.handle.net/10668/28507
T2  - Neuro-Oncology
AB  - Background. Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAF(V600)-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAF(V600)-mutant melanoma and brain metastasis...
LA  - en
PB  - Oxford University Press
KW  - Brain metastasis
KW  - Encorafenib and binimetinib
KW  - Melanoma
KW  - Radiotherapy
KW  - Targeted therapy
KW  - Proto-Oncogene Proteins B-raf
KW  - Alanine Transaminase
KW  - Progression-Free Survival
KW  - Medical Futility
KW  - Brain Neoplasms
KW  - Steroids
KW  - Adrenal Cortex Hormones
TI  - Encorafenib and binimetinib followed by radiotherapy for patients with BRAF<SUP>V600</SUP>-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
TY  - research article
VL  - 26
ER  -